1. Home
  2. LVTX

as 05-30-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.

Founded: 2016 Country:
Netherlands
Netherlands
Employees: N/A City: UTRECHT
Market Cap: 33.1M IPO Year: 2021
Target Price: $1.75 AVG Volume (30 days): 50.0K
Analyst Decision: Hold Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.04 EPS Growth: N/A
52 Week Low/High: $0.85 - $2.53 Next Earning Date: 05-14-2025
Revenue: $4,990,000 Revenue Growth: -60.20%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

LVTX Daily Stock ML Predictions

Share on Social Networks: